Clinical trials: Graft vs Host Disease
Graft Versus Host Disease
Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation
Investigators hypothesize that combination of ATLG with PTCy in matched or mismatched unrelated hematopoietic stem cell transplantation will reduce acute and chronic GVHD incidence.
- Trial name
- NCT03357159
- Testing
- Cyclophosphamide, anti-human T-lymphocyte immunoglobulin (ATLG)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Graft vs Host Disease, Immune System Disorders
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against…
- Trial name
- NCT00224874
- Testing
- Etanercept, Mycophenolate Mofetil, Denileukin Diftitox
- Where
- 19 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Graft Versus Host Disease
Study of MEDI 507 in the Treatment of Pediatric Patients
To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.
- Trial name
- Pediatric GvHD (NCT00813618)
- Testing
- MEDI-507
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- MedImmune LLC
Hematopoietic Stem Cell Transplantation
Lymphocyte Count, ATG Dose and Incidence and Severity of GVHD in Pediatric Recipients of HSCT
Despite increasing success rate in hematopoietic stem cell transplantation (HSCT) control of graft versus host disease (GVHD) remains a significative burden in mortality and morbidity.
- Trial name
- NCT04869254
- Testing
- Lower lymphocyte/ATG ratio, Higher lymphocyte/ATG ratio
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- IRCCS Burlo Garofolo
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- HATCY (NCT02999854)
- Testing
- ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor
- Where
- 42 sites in United States, Belgium and 11 more
- Volunteers
- 63 people
- Sponsor
- Kiadis Pharma
Migraine
An Open Label Extension of a Study of Topiramate in Chronic Migraine.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of headaches in adults with chronic migraine. Topiramate has been approved to prevent migraine headaches.
- Trial name
- NCT00210873
- Testing
- topiramate
- Volunteers
- 200 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Xerostomia, Graft-versus-host-disease
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands.
- Conditions
- Xerostomia, Graft-versus-host-disease, Sjogren's Disease
- Trial name
- NCT06392711
- Testing
- Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Wisconsin, Madison
Bronchiolitis Obliterans, Lung Transplantation
Montelukast in Bronchiolitis Obliterans Syndrome
Chronic rejection (or Bronchiolitis Obliterans syndrome-BOS) is a major cause of mortality and morbidity after lung transplantation.
- Conditions
- Bronchiolitis Obliterans, Lung Transplantation, Graft Rejection
- Trial name
- MLK002 (NCT01211509)
- Testing
- Montelukast
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Bone Marrow Transplant Complications, Graft Versus Host Disease
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and…
- Conditions
- Bone Marrow Transplant Complications, Graft Versus Host Disease, Infection Viral, Engraft Failure
- Trial name
- NCT03818334
- Testing
- Cyclophosphamide, ATG
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital Israelita Albert Einstein
Graft Versus Host Disease, Lymphoma
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an immune response that will kill cancer cells.
- Trial name
- NCT00003414
- Testing
- aldesleukin, recombinant interferon gamma, busulfan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Graft-Versus-Host Disease
Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment
Now it is commonly accepted that MSC produce an immune-tolerant environment in different settings. It has been shown (mainly for BM-MSC) that MSC can down-regulate T cells activation.
- Trial name
- MSCGVHD (NCT00749164)
- Testing
- MSC transplantation
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
This Phase II clinical trial was designed for patients with hematologic malignancies in need of donor peripheral blood stem cell transplant, and have no HLA matched donor.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT01116232
- Testing
- anti-thymocyte globulin, rituximab, sirolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Chronic Low Back Pain
Exposure Therapy and Safety-seeking Behavior in Chronic Low Back Pain
RATIONALE: Exposure in vivo therapy aims to reduce pain-related fear - a key maintaining factor of chronic low back pain- while increasing level of daily functioning, despite the pain.
- Trial name
- NCT01971151
- Testing
- Exposure therapy
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Maastricht University Medical Center
Graft -Versus-host-disease, aGVHD
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD
- Trial name
- NCT07246031
- Testing
- BPC-2001
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- BioPhoenix Co., Ltd.
Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
This is a single arm open label phase 2 study evaluating the potential effect of ixazomib on the prevention of recurrent or late acute graft-versus-host disease (GVHD) and chronic GVHD at 1-year following reduced intensity (RI)…
- Trial name
- NCT03082677
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease
Efficacy and Safety of FMT Capsule Treating Steroid-refractory GI-aGvHD
Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD) is a complication of allogeneic stem cell transplant which is usually treated with steroids.
- Trial name
- NCT04622475
- Testing
- Fecal Microbiota Transplant (FMT) Capsule
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Graft vs Host Disease, Malignancy
Abatacept as GVHD Prophylaxis Phase 2
This is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or…
- Trial name
- NCT01743131
- Testing
- Abatacept
- Where
- 14 sites in United States, Canada
- Volunteers
- 186 people
- Sponsor
- Boston Children's Hospital
Graft Versus Host Disease in Eye
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease.
- Trial name
- NCT05294666
- Testing
- Cyclosporine, tacrolimus
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Peking University Third Hospital
GVHD
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis. In our previous study, the investigators demonstrated that the standard dose PTCY of 50mg/kg with tacrolimus and…
- Trial name
- NCT06000982
- Testing
- PTCY
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.